Sector
PharmaceuticalsOpen
₹30,305.2Prev. Close
₹30,318Turnover(Lac.)
₹1,510.38Day's High
₹30,318Day's Low
₹29,616.252 Week's High
₹31,898.9552 Week's Low
₹25,200Book Value
₹2,233.55Face Value
₹10Mkt Cap (₹ Cr.)
63,019P/E
48.26EPS
627.98Divi. Yield
1.359 May 2024
12:00 AM
Dividend
Dividend Amount: 410
Record Date: 19 Jul, 2024
9 May 2024
12:00 AM
AGM
Announcement Date: 09 May, 2024
28 Jan 2025
12:00 AM
Board Meeting
Agenda : Audited Result
EBITDA increased by 10.2% to ₹391.1 Crore in the first quarter of this fiscal year, up from ₹355 Crore the previous year.
Here are some of the stocks that may see significant price movement today: Godrej Consumer Products, Hindalco Industries, Abbott India, etc.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 21.25 | 21.25 | 21.25 | 21.25 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,677.64 | 3,167.29 | 2,798.54 | 2,580.91 |
Net Worth | 3,698.89 | 3,188.54 | 2,819.79 | 2,602.16 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 4,919.27 | 4,310.02 | 4,093.14 | 3,298.5 |
yoy growth (%) | 14.13 | 5.29 | 24.09 | 13.64 |
Raw materials | -2,657.21 | -2,390.92 | -2,315.65 | -1,904.74 |
As % of sales | 54.01 | 55.47 | 56.57 | 57.74 |
Employee costs | -579.46 | -492.65 | -476.1 | -393.69 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,079.73 | 925.95 | 802.69 | 621.48 |
Depreciation | -66.1 | -58.13 | -59.6 | -16.18 |
Tax paid | -281.03 | -235.26 | -209.75 | -220.26 |
Working capital | 201.35 | 142.23 | 751.83 | 336.01 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.13 | 5.29 | 24.09 | 13.64 |
Op profit growth | 18.04 | 21.81 | 44.22 | 32.01 |
EBIT growth | 16.37 | 16.39 | 29.73 | 42.59 |
Net profit growth | 15.63 | 16.48 | 47.78 | 45.02 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Munir Shaikh
Non Executive Director
Kaiyomarz Marfatia
Non Executive Director
Ambati Venu
Independent Director
Anisha Motwani
Independent Director
Sudarshan Jain
Independent Director
Shalini Kamath
Non Executive Director
Sabina Ewing
Non Executive Director
Mahadeo Karnik
Managing Director
SWATI ROHAN DALAL
Non Executive Director
Alison Davies
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Abbott India Ltd
Summary
Abbott India Ltd. is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country. The Company sells its products through independent distributors primarily within India. It provides products and solutions across various therapeutic areas such as Womens Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc. Its global products include Brufen, Prothiaden, Thyronorm and Leptos.The company has four divisions. The Primary Care division markets products in the areas of pain management and gastroenterology. The Specialty Care-Methabolics and Urology division provides solutions in the areas of thyroid, obesity, diabetes and benign prostatic hyperplasia. The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments. Hospital Care offers products in the field of anesthesiology and neonatology, such as Forane, Sevorane and Survanta.Abbott India Ltd was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1, 1971, thereafter to Boots Pharmaceuticals Ltd on January 1, 1991. In October 31, 1995 the name was changed to Knoll Pharmaceuticals Ltd, and in July 1, 2002, they got their present name Abbott India Ltd.In the year 200
Read More
What is the Abbott India Ltd share price today?
The Abbott India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹29656 today.
What is the Market Cap of Abbott India Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Abbott India Ltd is ₹63019.00 Cr. as of 02 Apr ‘25
What is the PE and PB ratio of Abbott India Ltd?
The PE and PB ratios of Abbott India Ltd is 48.26 and 18.29 as of 02 Apr ‘25
What is the 52 Week High and Low of Abbott India Ltd?
The 52-week high/low is the highest and lowest price at which a Abbott India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Abbott India Ltd is ₹25200 and ₹31898.95 as of 02 Apr ‘25
What is the CAGR of Abbott India Ltd?
Abbott India Ltd's CAGR for 5 Years at 14.19%, 3 Years at 20.07%, 1 Year at 10.16%, 6 Month at 4.49%, 3 Month at 0.99% and 1 Month at -2.78%.
What is the shareholding pattern of Abbott India Ltd?
The shareholding pattern of Abbott India Ltd is as follows:
Promoters - 74.99 %
Institutions - 9.17 %
Public - 15.84 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
